What SOLVO Biotechnology does

SOLVO Biotechnology is a specialty biotechnology company focused exclusively on drug transporter research and ADME/Tox (absorption, distribution, metabolism, excretion, and toxicology) services for the pharmaceutical industry. The company develops and commercializes proprietary assay platforms, reagent kits, cryopreserved cell lines, and membrane preparations that enable drug-drug interaction (DDI) studies targeting 63+ human membrane transporters, including efflux transporters (MDR1/P-gp, BCRP, MRPs, BSEP) and uptake transporters (OATs, OATPs, OCTs, MATEs). Core proprietary technologies include the HepatoPac micropatterned co-culture system, B-Clear sandwich-cultured hepatocyte assay, PREDEASY ATPase assay kits, PREDIVEZ vesicular transport kits, TranSelect cryopreserved cells, and PreadyPort/CACOREADY ready-to-use cell monolayers. The company also offers metabolism services covering CYP450 inhibition, induction, and phenotyping, metabolic stability, and UGT inhibition assays.

The business operates a hybrid model combining catalog product sales (kits, membrane preparations, cell lines) with contract research services performed at SOLVO laboratories, plus licensing of cell lines and proprietary assay systems. Pricing is quote-based with multi-year contracts gated behind business/institution email registration. SOLVO serves global pharmaceutical companies engaged in drug discovery and development as its primary customer segment, with academic and research institutions as a secondary segment, and supports regulatory submissions to the FDA and EMA. Distribution combines direct sales with regional partners including MilliporeSigma (North America), KAC (Japan, South Korea, China, Singapore, Australia, New Zealand), and Merck Japan. The company holds ISO 9001:2015 certification and has a 20+ year track record of launching 10-20 new products and services annually in response to evolving transporter science and regulatory guidance.

Since 2022, SOLVO has operated as a wholly-owned subsidiary of Charles River Laboratories, gaining integration into a global preclinical CRO's sales, distribution, and client infrastructure while maintaining its Szeged, Hungary headquarters and branded product portfolio. R&D has historically been supported by multiple Hungarian government grant programs (GINOP, GOP, PIACI KFI), and the company maintains scientific authority through the Transporter Book (4th edition covering 63 transporters with 1,500+ references), peer-reviewed publications, the Meet the Experts webinar and conference series, and collaborations with academic institutions including the Hungarian Academy of Sciences and the University of Szeged.

Name

SOLVO Biotechnology

Legal name

Solvo Biotechnology

Website

https://solvobiotech.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

501–1,000 employees

Short description

SOLVO Biotechnology is a Charles River subsidiary that develops proprietary assay kits, cell lines, and contract research services for drug transporter studies, serving global pharmaceutical companies conducting FDA/EMA-compliant drug-drug interaction research.

Ownership category

akta.pro rank

Product category

Drug Transporter Assays and ADME/Tox Services

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

DMPK / ADME & Bioanalysis (HLAGAFAC)

akta.pro secondary industry

In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM)

Keywords

• Drug transporter assays
• ADME/Tox services
• Membrane vesicle preparations
• Drug interaction studies
• Preclinical contract research

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Transporter Products: Sale of transporter assay kits including efflux transporter kits (MDR1, BCRP, MRPs), uptake transporter kits, membrane preparations, ready-to-use monolayers, ATPase assay kits (PREDEASY), vesicular transport reagent kits (PREDIVEZ), and cryopreserved cells (TranSelect).
2. Transporter Services: Contract research services including uptake transporter assays, efflux transporter services, Caco-2 services, hepatocyte uptake assays, vesicular transport assays, monolayer assays, and ATPase assays performed at SOLVO laboratories.
3. Metabolism Services: CYP450 inhibition, induction, and phenotyping services; metabolic stability studies; UGT inhibition assays for drug development support.
4. Licensing: Cell line licenses and technology licensing for proprietary assay systems and cell models.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Core offering

SOLVO Biotechnology sells proprietary drug transporter assay kits, membrane vesicle preparations, cryopreserved transporter-expressing cell lines, and ready-to-use hepatocyte and Caco-2 monolayer products. It also performs contract research services including transporter interaction assays, Caco-2 permeability, sandwich-cultured hepatocyte (B-Clear) studies, CYP450 and UGT metabolism assays, and drug-induced liver injury (DILIScreen) testing for pharmaceutical drug development and regulatory submissions.

Product overview

SOLVO Biotechnology is a Charles River company offering a comprehensive portfolio of products and services for drug transporter research and ADME/Tox studies. The product portfolio includes: Membrane Preparations (inside-out vesicles for ABC transporter assays), Uptake Transporter Kits, Efflux Transporter Kits (including PREDEASY™ ATPase and PREDIVEZ™ vesicular transport reagent kits), Ready-to-use Monolayers (PreadyPort™, CACOREADY™), HepatoPac® micropatterned co-cultures, and TranSelect™ cryopreserved cells. The service portfolio covers Transporter Services (Uptake, Efflux, Caco-2, Hepatocyte Uptake, Lysosomal Trapping, Hepatic Kp,uu Determination, Proximal Tubule Cell Monolayer, B-Clear®, DILIScreen) and Metabolism Services (CYP450 Inhibition/Induction/Phenotyping, Metabolic Stability, UGT Inhibition). The company launches 10-20 new products/services annually based on latest transporter science and regulatory requirements from FDA/EMA.

Differentiator

Problem solved

Functional benefit

Brands

• HepatoPac®: Hepatocyte-based product for hepatic drug transport studies
• B-Clear®
• PreadyPort™
• PREDEASY™
• PREDIVEZ™
• TranSelect™
• CACOREADY™

Products and services

• Membrane Preparations Crude and sucrose-gradient purified inside-out membrane vesicles for studying drug-ABC transporter interactions via vesicular transport and ATPase assays. Sold to pharmaceutical and academic researchers running transporter studies.
• Uptake Transporter Kits Assay kits for measuring solute carrier (SLC) uptake transporter activity, covering OAT, OATP, OCT, and MATE families. For pharmaceutical DMPK labs studying drug uptake into cells.
• Efflux Transporter Kits Assay kits for measuring ABC efflux transporter activity and inhibition, including MDR1/P-gp, BCRP, MRP, and BSEP. For pharmaceutical researchers characterizing drug efflux and DDI risk.
• Ready-to-use Monolayers (PreadyPort) Pre-formed ready-to-use cell monolayers for Caco-2 permeability and transporter interaction studies. For pharmaceutical DMPK labs needing standardized monolayer formats.
• HepatoPac Micropatterned co-culture systems using HepaRG cells for long-term hepatic drug metabolism, transporter studies, and DILI/cholestasis assessment. For pharmaceutical hepatotoxicity and metabolism programs.
• PREDEASY ATPase Assay Kits and Controls ATPase assay reagent kits and controls for detecting transporter-drug interactions via ATP hydrolysis measurement on MDR1/P-gp, BCRP, BSEP, and MRP2. For pharmaceutical researchers running in-house ATPase screens.
• PREDIVEZ Vesicular Transport Reagent Kits Vesicular transport reagent kits for direct measurement of ATP-dependent substrate translocation via MDR1/P-gp, BCRP, MRP2, MRP3, and MRP5. For pharmaceutical efflux transporter screening.
• TranSelect Cryopreserved Cells Cryopreserved cells expressing specific SLC uptake transporters (OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K). Ready-to-use for pharmaceutical uptake transporter studies.
• CACOREADY Ready-to-use Caco-2 cell-based assay system for intestinal permeability and drug transport studies. For pharmaceutical permeability and formulation screening programs.
• Transporter Contract Research Services Contract research services including uptake transporter assays, efflux transporter profiling, Caco-2 permeability, sandwich-cultured hepatocyte (B-Clear) uptake and biliary excretion studies, lysosomal trapping, hepatic Kp,uu determination, renal proximal tubule cell monolayer assays, and DILIScreen DILI prediction. Performed at SOLVO laboratories for pharmaceutical clients needing regulatory-grade transporter data.
• Metabolism Services Contract metabolism services including CYP450 inhibition, induction, and phenotyping assays, in vitro metabolic stability studies, and UGT inhibition screening. For pharmaceutical drug metabolism and DDI programs.
• Cell Line and Technology Licensing Licensing of proprietary cell lines (including HepatoPac, B-Clear) and associated assay technologies to third parties. For pharmaceutical and research organizations needing access to validated hepatic and transporter models.

Quantifiable outcome

• Regulatory-compliant DDI studies meeting FDA and EMA requirements
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Charles River LaboratoriescoreOthersSOLVO Biotechnology is a wholly-owned subsidiary of Charles River Laboratories. This provides integration into a global preclinical contract research organization with extensive pharmaceutical industry relationships and distribution capabilities.
• MTA Kémiai Kutatóintézet Farmakobiokémiai OsztályminorStrategic or Co-development PartnerCollaboration with the Hungarian Academy of Sciences Chemical Research Institute's Pharmacobiochemistry Department for hepatocyte and cholestasis research within the GOP-1.1.1-09/1-2009-0054 projekt.
• Szegedi Tudományegyetem ÁOK Orvosi Vegytani IntézetminorStrategic or Co-development PartnerCollaboration with University of Szeged's Medical Chemistry Institute for prodrug absorption research within the GOP-1.1.1-09/1-2009-0055 projekt.
• KAC Co., Ltd.coreChannel Partner/ Reseller/ DistributorKAC serves as distributor of SOLVO products in Japan and South Korea, mediating both product sales and SOLVO services across these markets.
• MilliporeSigma (Merck KGaA)coreChannel Partner/ Reseller/ DistributorMilliporeSigma, a business of Merck KGaA, Darmstadt, Germany, serves as non-exclusive distributor of SOLVO ready-to-use kits, membrane preparations, and reagents in North America. Merck also distributes in APAC countries.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Cyprotex (Evotec): An Evotec-owned contract research organization offering in vitro ADME, DMPK, and drug transporter assay services to pharmaceutical and biotech clients. Direct overlap with SOLVO in transporter-mediated DDI studies, Caco-2, and hepatocyte assays.
• Sekisui Xenotech: Specialized CRO offering drug transporter and metabolism services including transfected cell lines, hepatocyte products, and DDI study packages. Closest functional peer in transporter assay science.
• Eurofins Discovery (Eurofins Scientific): Discovery and DMPK services arm of Eurofins Scientific providing in vitro ADME, transporter, and pharmacology services to pharma. Direct competitor in the DMPK/transporter assay market.
• BioIVT: Supplier of biological specimens, primary hepatocytes, and transporter-related reagents and services. Direct competitor in cryopreserved hepatocytes and transporter assay reagents.
• QPS Holdings: Global CRO with DMPK, bioanalytical, and translational pharmacology services including transporter studies. Direct overlap in preclinical DMPK and ADME offerings for pharma clients.
• Pharmaron: Integrated CRO/CDMO offering in vitro ADME, DMPK, and drug transporter services alongside discovery, CMC, and clinical capabilities. Competes for the same pharma DDI/transporter study spend.

Broad incumbents

• Thermo Fisher Scientific: Global life sciences tools and CRO giant with cell biology reagents, cell lines, and contract DMPK services. Competes with SOLVO broadly in life-science reagents and adjacent CRO services.
• MilliporeSigma (Merck KGaA): Life sciences tools business of Merck KGaA that already serves as SOLVO's North American distributor and competes with broader assay and reagent catalogs including cell biology and biochemistry.

Regional players

• Aragen Life Sciences: India-headquartered CRO with discovery, DMPK, and in vitro ADME/transporter services. Competes for outsourced DMPK/transporter work with cost-advantaged positioning in Asia.

Others

• Corning Life Sciences: Supplier of cell culture products, transwell inserts, and assay platforms that overlap with SOLVO's cell-based monolayer and Caco-2 workflows. An adjacent/ecosystem player rather than a direct service competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/solvobiotech
• Facebookfacebook.com/solvobiotech
• LinkedInlinkedin.com/company/633600

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SOLVO Biotechnology